Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone in Pelizaeus-Merzbacher disease
NL-OMON51993Phase 2Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in Pelizaeus-Merzbacher disease (PMD) and hypomyelinating leukodystrophy (HLD), sponsored by Vrije University Medical Center. Primary endpoint: Gross motor function. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
deferiprone
03
Conditions
Pelizaeus-Merzbacher disease (PMD)hypomyelinating leukodystrophy (HLD)
Beyond the preview
Go deeper on NL-OMON51993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51993.